An interim safety analysis of hepatocellular carcinoma patients administrating oral vitamin K with or without sorafenib
Korean Journal of Hepato-Biliary-Pancreatic Surgery
;
: 1-5, 2015.
Article
in English
| WPRIM
| ID: wpr-47880
ABSTRACT
BACKGROUNDS/AIMS:
Vitamin K may plays a role in controlling hepatocellular carcinoma (HCC) cell growth. In this study, we intended to present 5-year experience of 72 patients receiving oral vitamin K with or without sorafenib. Its end-point was to evaluate the safety of combination therapy using sorafenib and vitamin K.METHODS:
An interim analysis was performed as a single-arm cross-sectional study, including 72 HCC patients who underwent liver resection or transplantation and administered oral vitamin K2 alone (n=47) or with sorafenib (n=25).RESULTS:
In all patients, administration of vitamin K2 analog 45 mg/day did not show any noticeable adverse side-effect during vitamin K therapy of 23.3+/-10.6 months, except for one patient who experienced skin rash at the third day of vitamin K therapy. In 25 patients receiving sorafenib and vitamin K for 6 months or longer, any noticeable adverse side-effect suspected of vitamin K origin was not identified yet. A small proportion of patients showed unexpectedly favorable anti-tumor effects after use of vitamin K with or without sorafenib.CONCLUSIONS:
Because add-on of oral vitamin K did not increase the adverse side-effects of sorafenib, a combination therapy with these two agents appears to be worthy of further clinical trial with an expectation of synergistic therapeutic effects.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Vitamin K
/
Cross-Sectional Studies
/
Carcinoma, Hepatocellular
/
Vitamin K 2
/
Exanthema
/
Liver
/
Neoplasm Metastasis
Type of study:
Controlled clinical trial
/
Observational study
/
Prevalence study
/
Risk factors
Limits:
Humans
Language:
English
Journal:
Korean Journal of Hepato-Biliary-Pancreatic Surgery
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS